Patents by Inventor Stian FOSS

Stian FOSS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IGA FC AND IGG FC TANDEM PROTEIN CONSTRUCTS
    Publication number: 20250002602
    Abstract: The present invention provides a protein construct comprising a human IgA Fc region and a human IgG Fc region, wherein the C-terminals of the human IgA Fc region are connected to the N-terminals of the human IgG Fc region. Such constructs can further comprise a targeting domain. Compositions comprising said constructs and therapeutic uses of said constructs are also provided.
    Type: Application
    Filed: November 7, 2022
    Publication date: January 2, 2025
    Inventors: Jan Terje ANDERSEN, Stian FOSS, Simone MESTER
  • ANTIBODY VARIANTS
    Publication number: 20240343793
    Abstract: The present invention relates to antibodies which bind to TNF? and exhibit modified FcRn-binding. The antibodies of the invention have good effector functions and/or pharmacokinetic properties.
    Type: Application
    Filed: June 3, 2024
    Publication date: October 17, 2024
    Applicant: Tillotts Pharma AG
    Inventors: Esther Maria FURRER, Stian FOSS, Jan Terje ANDERSEN, Inger SANDLIE
  • Antibody variants
    Patent number: 11999781
    Abstract: The present invention relates to antibodies which bind to TNF? and exhibit modified FcRn-binding. The antibodies of the invention have good effector functions and/or pharmacokinetic properties.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: June 4, 2024
    Assignee: Tillotts Pharma AG
    Inventors: Esther Maria Furrer, Stian Foss, Jan Terje Andersen, Inger Sandlie
  • ENGINEERED IMMUNOGLOBULINS WITH ALTERED FCRN BINDING
    Publication number: 20220348690
    Abstract: The present invention relates to compositions and methods for antibody-mediated therapy. In particular, provided herein are engineered immunoglobulins with altered half-life.
    Type: Application
    Filed: April 12, 2022
    Publication date: November 3, 2022
    Applicant: UNIVERSITETET | OSLO
    Inventors: Jan Terje ANDERSEN, Stian FOSS, Inger SANDLIE
  • Engineered immunoglobulins with altered FcRn binding
    Patent number: 11319383
    Abstract: The present invention relates to compositions and methods for antibody-mediated therapy. In particular, provided herein are engineered immunoglobulins with altered half-life.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: May 3, 2022
    Assignee: Universitetet | Oslo
    Inventors: Jan Terje Andersen, Stian Foss, Inger Sandlie
  • ENGINEERED IMMUNOGLOBULINS WITH ALTERED FCRN BINDING
    Publication number: 20190077883
    Abstract: The present invention relates to compositions and methods for antibody-mediated therapy. In particular, provided herein are engineered immunoglobulins with altered half-life.
    Type: Application
    Filed: March 14, 2017
    Publication date: March 14, 2019
    Applicant: UNIVERSITETET I OSLO
    Inventors: Jan Terje ANDERSEN, Stian FOSS, Inger SANDLIE